{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8"}]}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4"}]}],"title":"Week 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4"}]}],"title":"Week 20"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"title":"Week 28"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"}]}],"title":"Week 36"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"title":"Week 44"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3"}]}],"title":">= Week 52"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0"}]}],"title":"no objective response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"}],"units":"Participants"}],"description":"Time to objective response was defined as the number of days from the start of treatment to the first recorded objective response. Patients who did not experience objective response during the study were censored at the time of treatment discontinuation.\n\nThe results are provided as the percentage of participants for this Outcome Measure.","groups":[{"description":"Patients in the four initial cohorts are combined in the efficacy presentations. Patients start once daily oral treatment of BIBW 2992 (Afatinib) at 50 mg before protocol amendment 2 (17 Dec 2008), until progression or undue adverse events (AEs) development. Patients can be dose-reduced up to two times if needed after temporary interruption of treatment due to drug- related AEs. After protocol amendment 2, the starting dose of BIBW 2992 was reduced to 40 mg, with 2 possible dose reductions if needed after temporary dose interruption due to drug-related AEs.","id":"OG000","title":"Afatinib"}],"paramType":"NUMBER","populationDescription":"Treated set","reportingStatus":"POSTED","timeFrame":"Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.","title":"Time to Objective Response","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}